AI Getting Better at Detecting Skin Cancer
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Nov. 3, 2023 -- Artificial intelligence (AI) is increasingly accurate in detecting skin cancer, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Oct. 11 to 14 in Berlin.
Kashini Andrew, M.B.B.S., from the University Hospitals Birmingham NHS Foundation Trust in the United Kingdom, and colleagues examined improvement in the sensitivity of the detection of skin cancers with continued improvement of the AI algorithm (upgraded twice since May 2020) using previously collected data (22,356 patients assessed over 2.6 years).
The researchers found that the latest version of AI software was highly sensitive in detecting all skin cancers (99.5 percent), precancers (92.5 percent), and melanoma (100 percent), with improved sensitivity observed over time. Out of 190 cancers, AI missed one cancer diagnosis -- a basal cell carcinoma identified at the second read by the safety-net dermatologist. The latest algorithm also showed a high specificity in identifying benign lesions (75.3 percent). Compared with version 1, the researchers note a slight drop in specificity for benign lesions, a potential trade-off for increased sensitivity for malignant lesions. The rate of overturn of the diagnosis from benign to skin cancer was 0.1 percent, which was a significant improvement from version 1. The investigators estimated that the latest version prevented more than 2,000 face-to-face appointments in secondary care.
"The role of AI in dermatology and the most appropriate pathway are debated," Andrew said in a statement. "Further research with appropriate clinical oversight may allow the deployment of AI as a triage tool. However, any pathway must demonstrate cost-effectiveness, and AI is currently not a standalone tool in dermatology. Our data shows the great promise of AI in future provision of health care."
Source: HealthDay
Posted : 2023-11-03 22:36
Read more
- Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
- AAP Endorses New Algorithm for Critical Congenital Heart Disease Screening
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
- Faster Psychotherapy Use Seen in Some Socioeconomically Advantaged Groups
- Biomarkers of Insulin Resistance Are Risk Factors for Aortic Stenosis
- Poor Control Over Aspects of Work Linked to Physician Burnout
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions